Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 18/20 | 0.73 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702377 | 0.95 | NR1H4 (0.69) | NR1H4MRGPRX4 | |
| SCHEMBL16702648 | 0.94 | NR1H4 (0.66) | NR1H4 | |
| SCHEMBL16702125 | 0.93 | NR1H4 (0.63) | NR1H4 | |
| SCHEMBL16702362 | 0.93 | NR1H4 (0.68) | NR1H4 | |
| SCHEMBL16701974 | 0.92 | NR1H4 (0.73) | NR1H4 | |
| SCHEMBL16702178 | 0.92 | NR1H4 (0.59) | NR1H4 | |
| SCHEMBL16702091 | 0.89 | NR1H4 (0.74) | NR1H4 | |
| SCHEMBL16703486 | 0.88 | NR1H4 (0.64) | NR1H4 | |
| SCHEMBL16709795 | 0.88 | NR1H4 (0.61) | NR1H4 | |
| SCHEMBL18191669 | 0.87 | NR1H4 (0.57) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | claimed |
| EP-3065738-B1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | claimed |
| US-9682939-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | claimed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | claimed |
| EP-3065738-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-09-14 | — | — | EP | claimed |
| WO-2015069666-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2015-05-14 | — | — | WO | claimed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| US-10077240-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2018-09-18 | — | — | US | disclosed |
| US-9682939-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| EP-3065738-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069666-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069666-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077240-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885 |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885 |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885 |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885 |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MRGPRX4 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.